Sign In
Free Newsletter
GlaxoSmithKline wins takeover bid for Human Genome
U.K. drug maker GlaxoSmithKline has secured its takeover of longtime partner Human Genome Sciences after agreeing to pay more, a move to expand GSK’s drug portfolio in crucial areas: biologic […]
Report: GSK in deal talks with Human Genome
NEW YORK — GlaxoSmithKline PLC is reportedly talking this weekend with Human Genome Sciences Inc. about its $2.6 billion offer for the Rockville-based biotech company. British drug maker GlaxoSmithKline made […]
Human Genome adopts ‘poison pill’ measure
ROCKVILLE — Biotech drugmaker Human Genome Sciences Inc.’s board has adopted a “poison pill” shareholder rights plan to ward off unsolicited takeover bids, and it also has rejected a buyout […]
GlaxoSmithKline in takeover bid for Human Genome
LONDON — GlaxoSmithKline PLC has made an offer to take over Rockville-based drug maker Human Genome Sciences Inc. which values the company at nearly $2.6 billion. GlaxoSmithKline, which has profit-sharing […]
Human Genome rejects GlaxoSmithKline’s $2.59B bid
The decision by Rockville-based biotech drugmaker Human Genome Sciences Inc. to reject an unsolicited $2.59 billion takeover bid Thursday may increase the eventual sale price of the company, analysts said. […]
Rockville-based Human Genome Sciences gets approval for new lupus drug
Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based […]
Human Genome’s lupus drug wins approval
WASHINGTON — The Food and Drug Administration on Wednesday approved the first new drug to treat lupus in over 50 years, a milestone that medical experts say could prompt development […]
FDA scrutinizes benefit of long-awaited lupus drug
WASHINGTON — Federal health officials said Friday that the first new drug developed to treat lupus in decades relieves disease symptoms, but they questioned the significance of its benefits, which […]
